

Resource Summary Report

Generated by [RRID](#) on Sep 21, 2026

BD Biosciences: FACSymphony A5 Cell Analyzer

RRID:SCR_022538

Type: Tool

Proper Citation

BD Biosciences: FACSymphony A5 Cell Analyzer (RRID:SCR_022538)

Resource Information

URL: <https://www.bdbiosciences.com/en-us/products/instruments/flow-cytometers/research-cell-analyzers/bd-facsymphony-a5>

Proper Citation: BD Biosciences: FACSymphony A5 Cell Analyzer (RRID:SCR_022538)

Description: Flow cytometer as novel cell analyzer that leverages inherent benefits of flow cytometry and enables simultaneous measurement of up to 50 different characteristics of single cell.

Synonyms: BD FACSymphony A5

Resource Type: instrument resource

Keywords: Flow cytometer, cell analyzer, simultaneous measurement, instrument, equipment, USEDit

Availability: Restricted

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_022538.pdf

Resource Name: BD Biosciences: FACSymphony A5 Cell Analyzer

Resource ID: SCR_022538

Alternate IDs: Model_Number_FACSymphony_A5

Record Creation Time: 20220706T050140+0000

Record Last Update: 20260919T195523+0000

Ratings and Alerts

No rating or validation information has been found for BD Biosciences: FACSymphony A5 Cell Analyzer.

No alerts have been found for BD Biosciences: FACSymphony A5 Cell Analyzer.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sherif S, et al. (2026) A Three-Gene Interferon Signature Predicts Sustained Complete Remission in Pediatric AML Patients. *Cancers*, 18(9).

Rayes A, et al. (2026) Refractory infantile IPEX with Treg-restricted FOXP3null expression caused by a novel variant in FOXP3. *Journal of human immunity*, 2(3), e20250249.

Torrent C, et al. (2026) Long-term rapamycin treatment suppresses IL-17-producing gamma delta T cells and blunts neuroinflammation in aging. *PloS one*, 21(5), e0343183.

Nguyen TT, et al. (2026) NN-01-195, a Novel Conjugate of HSP90 and AURKA Inhibitors, Effectively Targets Solid Tumors. *Molecular cancer therapeutics*, 25(8), 1231.

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. *Cancer research communications*, 6(7), 1619.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Zhou L, et al. (2026) p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy. *Cancer discovery*, 16(3), 571.

Garg SK, et al. (2026) Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier. *Cell reports*, 45(3), 117050.

Bleve A, et al. (2025) ROR γ Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression. *Cancer discovery*, 15(7), 1505.

Umeda M, et al. (2025) Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia. *medRxiv : the preprint server for health sciences*.

Nattress CB, et al. (2025) Phenoscaping Reveals Multimodal ?? T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell-Mediated Immunomodulation. *Cancer research*,

85(22), 4415.

Foot J, et al. (2025) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. *Cancer research*, 85(5), 956.

Murphy KC, et al. (2025) MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. *Cancer research*, 85(22), 4359.

Yu CI, et al. (2024) Protocol to construct humanized mice with adult CD34+ hematopoietic stem and progenitor cells. *STAR protocols*, 5(3), 103155.

Niwa Y, et al. (2023) Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti-PD-1 Antibody. *Molecular cancer therapeutics*, 22(4), 499.